Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IBO vs IBG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IBO Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 7–2 Matrix Metrics)

IBO Overall Winner 6-Pillar Tally: IBO 2 – 1 IBG (3 Tie) Matrix Metrics: IBO 7 – 2 IBG

As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Innovation Beverage Group Limited (IBG) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). IBO carries a Unified Composite Score of 36.8/100 (SELL) at $4.96 (N/M Forward P/E, -12621.0% operating margin), whereas IBG carries 45.2/100 (HOLD) at $0.71 (N/M Forward P/E, -187.6% operating margin).

  • Composite vs. Pillar Nuance: While IBG currently prints a higher short-term Unified Composite Score (45.2/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (7–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. -187.6% operating margin) and revenue trajectory (+16.7% vs. -38.6% YoY).
  • Technical & Structure Timing Caution: IBO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.4); meanwhile IBG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IBO vs IBG
IBO NYSE American Head-to-Head Winner
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.96
-3.5% 1D
Market Cap $41.2M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol -6.75β · 120% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (71.0% over 20 days), RSI 62
RSI-14: 62.4 · SMA20: $4.12 · SMA50: $3.52
IBG NASDAQ
Innovation Beverage Group Limited Ordinary Shares
Beverages
$0.71
-8.86% 1D
Market Cap $3.0M
TTM Revenue $2.8M
Forward P/E N/M
Beta / 30D Vol 1.07β · 125% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 43.0 Fund 59.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.1%), weak momentum, RSI 44
RSI-14: 43.5 · SMA20: $0.81 · SMA50: $0.88

6-Pillar Scorecard Institutional Category Breakdown (IBO 2 – 1 IBG)

Columns: Metric · IBO · IBG
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E 0.4x N/M
PEG Ratio N/M N/M
EV / Revenue 18.2x 1.1x
2. Growth & Scale IBO
Revenue Growth (YoY) +16.7% -38.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.3M $2.8M
Market Cap $41.2M $3.0M
3. Profitability & Quality IBG
Gross Margin N/A 44.2%
Operating Margin -12621.0% -187.6%
Net Profit Margin 4247.4% -223.4%
Return on Equity (ROE) 71.2% -159.3%
4. Balance Sheet & Cash Flow IBO
Cash Generation (TTM) -$99M -$5.1M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.18 Book/Sh · 71.2% ROE -159.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Beverages - Wineries & Distilleries Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IBO (7) vs IBG (2)
Institutional Metric IBO IBG Criterion Row Edge
Market Capitalization
Scale
$41.2M $3.0M Larger Scale IBO
Trailing P/E Ratio
Valuation
0.4x N/M Lower Multiple IBO
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+16.7% -38.6% Higher Growth IBO
Operating Margin (TTM)
Profitability
-12621.0% -187.6% Higher Margin IBG
Net Profit Margin
Profitability
4247.4% -223.4% Higher Margin IBO
Return on Equity (ROE)
Capital Efficiency
71.2% -159.3% Higher ROE IBO
52-Week Range Position
Momentum
68% ($0–$7) 1% ($1–$6) Stronger Trend IBO
Beta / 30D Volatility
Risk Regime
-6.75β · 120% Vol 1.07β · 125% Vol Lower Realized Risk IBO
Unified Institutional Score
Composite Signal
36.8 / 100 (SELL) 45.2 / 100 (HOLD) Higher Composite IBG
Trailing 12M Revenue (USD)
Operating Scale
$2.3M $2.8M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 44.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.2x EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$99M ($1.18 Book/Sh · 71.2% ROE) -$5.1M EBITDA (-159.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IBO +97.09 pp
IBO: +85.07% · IBG: -12.02%
3M Horizon IBO +977.73 pp
IBO: +955.32% · IBG: -22.41%
6M Horizon IBO +834.51 pp
IBO: +821.42% · IBG: -13.09%
1Y Horizon IBO +933.6 pp
IBO: +872.55% · IBG: -61.05%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IBO vs IBG. Trailing 12-month operating profitability (IBO -12621.0% vs IBG -187.6%) and valuation multiples (IBO N/M vs IBG N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IBO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.3M
Gross MarginN/A
Op. Margin-12621.0%
ROE / Fwd P/E71.2% · N/M
IBG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.8M
Gross Margin44.2%
Op. Margin-187.6%
ROE / Fwd P/E-159.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IBO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IBO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IBG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IBG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IBO Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $41.2M market capitalization and -12621.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IBG Moat Profile Cyclical / Execution-Driven Positioning
Beverages - Wineries & Distilleries Operator
Competes within the Beverages - Wineries & Distilleries value chain with $3.0M market capitalization and -187.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IBO vs IBG Key Questions & Quantitative Answers

As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Innovation Beverage Group Limited (IBG) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). IBO carries a Unified Composite Score of 36.8/100 (SELL) at $4.96 (N/M Forward P/E, -12621.0% operating margin), whereas IBG carries 45.2/100 (HOLD) at $0.71 (N/M Forward P/E, -187.6% operating margin). Composite vs. Pillar Nuance: While IBG currently prints a higher short-term Unified Composite Score (45.2/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (7–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. -187.6% operating margin) and revenue trajectory (+16.7% vs. -38.6% YoY). Technical & Structure Timing Caution: IBO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.4); meanwhile IBG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IBO leads the Growth & Scale pillar: IBO posts +16.7% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (N/A gross margin, -12621.0% operating margin), compared with IBG at -38.6% YoY revenue growth and +0.0% YoY earnings growth on $2.8M TTM revenue (44.2% gross margin, -187.6% operating margin). On trailing 12-month operating scale, IBO generates $2.3M in USD-normalized revenue versus $2.8M for IBG. In operating R&D and SG&A reinvestment, IBO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IBG.

IBO and IBG trade at balanced relative valuation multiples. IBO trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and 18.2x EV/Revenue (unreported FCF margin), whereas IBG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IBO (71.2% ROE) versus IBG (-159.3% ROE) capital efficiency.

In options market volatility and institutional positioning, IBO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-6.75β · 120% Vol realized risk). By comparison, IBG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.07β · 125% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.